UCB reported EUR1.29B in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
Alcon AG USD 381M 337M Sep/2026
Almirall EUR 71.55M 41.32M Jun/2026
Amarin USD -2.26M 564K Dec/2025
argenx SE USD 486M 7M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bayer EUR 129M 698M Sep/2026
Genmab DKK 407M 182M Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
GRIFOLS EUR 394M 65M Sep/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lakefront Biotherapeutics EUR -41.17M 2.34M Sep/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 660M 437M Sep/2026
Novartis USD 5.14B 392M Sep/2026
Orion EUR 209.9M 33.3M Sep/2026
Recordati EUR 207.37M 3.61M Sep/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
UCB EUR 1.29B 571M Dec/2025
Unibail Rodamco EUR 844.1M 102.4M Dec/2025